Form 483

Kelix bio (Malta) Ltd. Form 483, 2022-12-16

FDA issued a Form 483 to Kelix bio (Malta) Ltd. on 2022-12-16 with 4 public-safe observations.

483· Form 483 issuedHuman Drugs4 observations

Kelix bio (Malta) Ltd. · Hal Far, Birzebbuga, Malta · Issued December 16, 2022

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

16 Dec 2022
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by William J Leonard

16 Dec 2022
21 CFR 211.192

Investigations of discrepancies, failures

Cited by William J Leonard

16 Dec 2022
21 CFR 211.42(c)(10)(v)

Cleaning System

Cited by William J Leonard

16 Dec 2022
21 CFR 211.63

Equipment Design, Size and Location

Cited by William J Leonard

Inspected site

KBKelix bio (Malta) Ltd.Hal Far, Birzebbuga, Malta

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(v)Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 4 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere